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The introduction of allosteric receptor–receptor interactions in G protein-coupled
receptor (GPCR) heteroreceptor complexes of the central nervous system (CNS) gave a
new dimension to brain integration and neuropsychopharmacology. The molecular basis
of learning and memory was proposed to be based on the reorganization of the homo-
and heteroreceptor complexes in the postjunctional membrane of synapses. Long-term
memory may be created by the transformation of parts of the heteroreceptor complexes
into unique transcription factors which can lead to the formation of specific adapter
proteins. The observation of the GPCR heterodimer network (GPCR-HetNet) indicated
that the allosteric receptor–receptor interactions dramatically increase GPCR diversity
and biased recognition and signaling leading to enhanced specificity in signaling.
Dysfunction of the GPCR heteroreceptor complexes can lead to brain disease. The
findings of serotonin (5-HT) hetero and isoreceptor complexes in the brain over the last
decade give new targets for drug development in major depression. Neuromodulation
of neuronal networks in depression via 5-HT, galanin peptides and zinc involve
a number of GPCR heteroreceptor complexes in the raphe-hippocampal system:
GalR1-5-HT1A, GalR1-5-HT1A-GPR39, GalR1-GalR2, and putative GalR1-GalR2-5-
HT1A heteroreceptor complexes. The 5-HT1A receptor protomer remains a receptor
enhancing antidepressant actions through its participation in hetero- and homoreceptor
complexes listed above in balance with each other. In depression, neuromodulation of
neuronal networks in the raphe-hippocampal system and the cortical regions via 5-HT
and fibroblast growth factor 2 involves either FGFR1-5-HT1A heteroreceptor complexes
or the 5-HT isoreceptor complexes such as 5-HT1A-5-HT7 and 5-HT1A-5-HT2A.
Neuromodulation of neuronal networks in cocaine use disorder via dopamine (DA)
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and adenosine signals involve A2AR-D2R and A2AR-D2R-Sigma1R heteroreceptor
complexes in the dorsal and ventral striatum. The excitatory modulation by A2AR
agonists of the ventral striato-pallidal GABA anti-reward system via targeting the
A2AR-D2R and A2AR-D2R-Sigma1R heteroreceptor complex holds high promise as
a new way to treat cocaine use disorders. Neuromodulation of neuronal networks
in schizophrenia via DA, adenosine, glutamate, 5-HT and neurotensin peptides and
oxytocin, involving A2AR-D2R, D2R-NMDAR, A2AR-D2R-mGluR5, D2R-5-HT2A and
D2R-oxytocinR heteroreceptor complexes opens up a new world of D2R protomer
targets in the listed heterocomplexes for treatment of positive, negative and cognitive
symptoms of schizophrenia.
Keywords: G protein-coupled receptor, addiction, schizophrenia, depression, heteroreceptor complexes,
oligomerization, serotonin receptor, dopamine receptor
FUNDAMENTALS OF GPCR
HETERORECEPTOR COMPLEXES, THEIR
ALLOSTERIC COMMUNICATION AND
THEIR FUNCTION
The concept of allosteric receptor–receptor interactions in
G protein-coupled receptor (GPCR) homo- and heteroreceptor
complexes of the central nervous system (CNS) gave a new
dimension to brain integration and neuropsychopharmacology
(Fuxe et al., 1983, 1998, 2008c, 2010b, 2014d; Zoli et al.,
1993; Liu et al., 2000; George et al., 2002; Guo et al., 2008;
Han et al., 2009; Borroto-Escuela et al., 2012a). Allosteric
receptor–receptor interactions made possible through receptor
oligomerization lead to novel receptor dynamics during which
the receptor protomers change their recognition, pharmacology,
signaling and trafficking and novel allosteric binding sites can
develop (Borroto-Escuela et al., 2011, 2012a; Fuxe et al., 2012a,
2014d; Fuxe and Borroto-Escuela, 2016). GPCR heteroreceptor
complexes can also involve ion channel receptors, receptor
tyrosine kinases (RTKs), sets of G protein interacting proteins,
ion channels and/or transmitter transporters (Fuxe et al., 2007;
Flajolet et al., 2008; Guo et al., 2008; Borroto-Escuela et al., 2012b,
2015c,d, 2016c; Fuxe and Borroto-Escuela, 2016; Di Liberto et al.,
2017). The allosteric interactions in such dynamic higher order
receptor complexes take place in an orchestrated spatio-temporal
fashion and participate in learning and formation of molecular
engrams for short and long term memory (Fuxe et al., 2014b;
Borroto-Escuela et al., 2015a). In addition, the NMDA receptor
complex is also now regarded as a multifunctional machine at
the glutamatergic synapse involving extrasynaptic and synaptic
D1R-NMDAR and D2R-NMDAR heteroreceptor complexes
(Liu et al., 2000, 2006; Zhang et al., 2016). There is a need to
improve our understanding of the molecular organization of
the receptor oligomers, their allosteric communication and the
features of the receptor interface (Borroto-Escuela et al., 2010c,
2014a; Tarakanov and Fuxe, 2010).
Recently the molecular basis of learning and memory was
proposed on the reorganization of the homo- and heteroreceptor
complexes in the postjunctional membrane of synapses
leading to changes in the prejunctional receptor complexes
to facilitate the pattern of transmitter release to be learned
(Fuxe et al., 2014b, Borroto-Escuela et al., 2015a). Long-term
memory may be created by the transformation of parts of the
heteroreceptor complexes into unique transcription factors
which can lead to the formation of specific adapter proteins
which can consolidate the heteroreceptor complexes into
long-lived complexes with conserved allosteric receptor–receptor
interactions (Fuxe et al., 2014a,b; Borroto-Escuela et al., 2015a).
Thus, the homo-heteroreceptor complexes are regarded as
highly dynamic assemblies formed or disrupted by integrated
synaptic and volume transmission signals. These events
are necessary for learning, and can become transformed into a
consolidated rigid state with conserved allosteric communication
representing molecular engrams resulting in a major long
term modulation of the neuronal networks. This molecular
plasticity change, whether transient or long term, can then
alter the patterns of outflow in the brain circuits and induce
transient and long-term changes in behaviors and cognitive
functions. In line with this hypothesis, blocking synaptic
removal of GluA2-containing AMPA receptors prevents the
natural forgetting of long-term memories (Migues et al.,
2016).
Of special relevance for structural plasticity, for example in
the dendritic tree and its spines, may be the recruitment of RTK
to the heteroreceptor complexes formed, which may result, for
example in synergistic increases in neurite densities and their
protrusions in primary neuronal cultures (Flajolet et al., 2008;
Borroto-Escuela et al., 2012b; Liebmann et al., 2016).
The concept of biased GPCR agonism meaning functional
selectivity was developed by Kenakin (2007, 2008, 2011). The
agonist stabilization of distinct active states in the receptor
conformation was suggested to be the mechanism involved
in producing activation of discrete signaling pathways of
GPCRs. In 1983/1985, receptor–receptor interactions and their
relevance for receptor diversity were presented based on studies
on neuropeptide/dopamine (DA) interactions (Agnati et al.,
1983a,b; Fuxe et al., 1983; Fuxe and Agnati, 1985). It is now
clear through the demonstration of the GPCR heterodimer
network (GPCR-HetNet; Borroto-Escuela et al., 2014a) that the
allosteric receptor–receptor interactions dramatically increases
GPCR diversity and biased recognition and signaling leading
to enhanced specificity in signaling (Fuxe et al., 2014f;
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Borroto-Escuela et al., 2015b; Fuxe and Borroto-Escuela, 2016).
The multiple origins of diversity and specificity in GPCRs were
elegantly clarified in 2005 (Maudsley et al., 2005).
DYSFUNCTION OF THE GPCR
HETERORECEPTOR COMPLEXES CAN
LEAD TO BRAIN DISEASE
A dysfunction or a disruption of the D2R heteroreceptor
complexes can be a molecular basis for a pathological change in
brain circuits. For example, an increase in D2R function leads
to alteration in the activity of glutamate prefrontal afferents
(Fuxe et al., 2008c), followed by development of schizophrenic
symptoms. Understanding these D2R heteroreceptor complexes
and their dysfunction in schizophrenia can lead to new strategies
for its treatment and for avoiding side-effects of antipsychotics
known to mainly act as D2R antagonists (Seeman, 2010),
including a way to optimize combined treatment or single
use of heterobivalent drugs targeting the D2R heteroreceptor
complexes in schizophrenia. This is inspired by the current
findings of various types of D2R heteroreceptor complexes
(Borroto-Escuela et al., 2014c; Ferraro et al., 2014; Fuxe et al.,
2014e, 2015; Pinton et al., 2015b; de la Mora et al., 2016).
With the discovery also of many 5-HT1A iso and
heteroreceptor complexes, like the 5-HT1A-5-HT7 (Renner
et al., 2012), the FGFR1-5-HT1A (Borroto-Escuela et al.,
2012b, 2013a, 2015c,d, 2016c) and the putative trimer complex
GalR1-GalR2-5-HT1A (Millón et al., 2014, 2016), an increased
understanding of the molecular basis of major depression was
obtained based on the 5-HT hypothesis of depression (Carlsson
et al., 1968; Figures 1, 2). Postjunctional 5-HT1A receptors
can strongly contribute to the mediation of the antidepressive
effects of 5-HT (Artigas, 2015). It is of high interest that in these
heteroreceptor complexes the receptor interacting proteins,
like the scaffolding protein p11 (Svenningsson, 2014; Milosevic
et al., 2017; Schintu et al., 2016), appear to play a substantial
role (Fuxe and Borroto-Escuela, 2016). In human suicide victims
reductions of p11 mRNA were established in hippocampus and
amygdala and antidepressants enhance the expression of p11 in
limbic regions of rodents (Svenningsson et al., 2013).
A significant role for the adaptor protein Disrupted in
Schizophrenia in D2R heteroreceptor complexes has also been
demonstrated (Su et al., 2014). This heterocomplex enhances
D2R-mediated glycogen synthase kinase-3 signaling and reduces
D2R internalization by agonists.
GPCR HETERORECEPTOR COMPLEXES
AS TARGETS FOR DRUG TREATMENT IN
BRAIN DISEASE
The GPCR heteroreceptor complexes in the CNS have become
exciting new targets for neurotherapeutics in Parkinson’s
disease, schizophrenia, substance use disorder, anxiety and
depression opening a new field in neuropsychopharmacology
(Portoghese, 2001; Soriano et al., 2009; Le Naour et al., 2013;
Fuxe et al., 2014e, 2015; Guidolin et al., 2015). Possible
novel strategies for targeting heteroreceptor complexes in
CNS disease are combined treatment with drugs targeting
two receptor protomers. To enhance compliance of patients,
fixed formulations of the two drugs can be developed which
give optimal pharmacokinetics for a time window of long
duration for the combined therapeutic actions. Dual acting
drugs targeting two protomers in the receptor complex can
also be developed as well as dual acting pro-drugs as a
potential and novel multi-target approach to treat CNS disease
(Borroto-Escuela et al., 2015e; Fuxe and Borroto-Escuela, 2015;
Fuxe et al., 2015). Heterobivalent drugs are other options
to selectively target heterodimers (Portoghese, 2001; Soriano
et al., 2009; Gutiérrez-de-Terán et al., 2017) such as D2R
antagonist and A2AR agonist pharmacophors targeting A2AR-
D2R heterodimers in cocaine use disorder (Fuxe and Borroto-
Escuela, 2016).
All these novel aspects on brain communication and
integration in heteroreceptor complexes lead to increased
understanding of the molecular basis of diseases in the CNS
and of their treatments. There is increased demand to know
and understand how the brain operates at the receptor level.
The heteroreceptor field is novel since receptors are usually
regarded to exist as monomers and this focused review
will show that the receptor field has moved into homo
and heterodimers and higher order homo and heteroreceptor
complexes through use of novel methodologies (Borroto-
Escuela et al., 2015b, 2016a). This research will therefore
substantially advance the receptor field. It introduces a
novel biological principle and neuropsychopharmacology which
targets the heteroreceptor complexes. The homo-heteroreceptor
complexes are also present inter alia in the peripheral nervous
system, the endocrine, the cardiovascular and gastrointestinal
systems. They represent new targets for drugs in molecular
medicine.
GPCR HETERORECEPTOR COMPLEXES
AND MAJOR DEPRESSION
The 5-HT hypothesis of major depression was developed in the
1960s inter alia through the demonstration of the ascending
5-HT neurons from the midbrain innervating the entire tel- and
diencephalon (Dahlstroem and Fuxe, 1964; Andén et al., 1966;
Fuxe and Dahlström, 2009), biochemical studies on tryptophan
and 5-HT (Coppen, 1967) and the 5-HT reuptake mechanism
in these neurons as well as its blockade by imipramine (Fuxe
and Ungerstedt, 1967; Carlsson et al., 1968). These observations
led to the development of the 5-HT selective reuptake inhibitors
(SSRI) for the treatment of depression. Over the decades a large
number of 5-HT receptor subtypes were identified belonging to
six families of G protein coupled 5-HT receptors, namely 5-HT1,
5-HT2, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 receptors, while the
5-HT3 receptor is coupled to an ion channel (Barnes and Sharp,
1999). Even before their discoveries there were indications that
classical antidepressants may block one particular type of 5-HT
receptors (Fuxe et al., 1977; Ogren et al., 1979). Today we
know that for antidepressant effect, 5-HT1A (postjunctional)
or 5-HT4 receptors should be activated, while 5-HT2A, 5-HT3
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FIGURE 1 | The ascending and descending 5-HT pathways from the rostral and caudal raphe nuclei are illustrated in the left panel. In the right panel the
5-HT immunoreactive nerve cell bodies and dendrites in the dorsal raphe are shown. The panorama of 5-HT1A heteroreceptor complexes including the 5-HT1A
isoreceptor complexes demonstrated in the dorsal raphe and in the dorsal hippocampus are given in the lower right part shown as heterodimers and in possible
balance with each other. They were described at the postjunctional level, likely in synaptic and extrasynaptic locations. The prejunctional existence of these 5-HT1A
heterocomplexes at the 5-HT nerve terminal still remains to be studied. They play a major role in the 5-HT modulation of the neuronal networks in the
raphe-hippocampal system together with the corresponding homoreceptor complexes and monomers. For the abbreviations see Supplementary Material.
and 5-HT7 should be blocked (Artigas, 2013). Thus, 5-HT
receptor subtype selective antagonists and agonists or drugs
acting at multiple 5-HT receptors and at serotonin transporter
(SERT) can be used to enhance the antidepressant effects of
SSRIs (Artigas, 2015). For the first time the hypothesis that the
development of major depression can involve an imbalance of
the receptor activity between different types of 5-HT isoreceptors
was introduced in 1991 (Fuxe et al., 1991; Figure 3). Further
findings of 5-HT hetero and isoreceptor complexes over the
last decade give new targets for drug development in major
depression. Below we discuss in detail the 5-HT hetero- and
isoreceptor structures, functions and allosteric receptor–receptor
interactions.
GalR-5-HT1A Heteroreceptor Complexes
Early studies showed that in membrane preparations from the
ventral limbic cortex Gal peptide (1–29) in the nanomolar
range reduced the affinity of [3H]-5HT1A agonist binding
sites (postjunctional sites) suggesting that Gal can reduce
5-HT1A recognition in this region (Fuxe et al., 1988). These
interactions represent an integrative antagonistic mechanism
in putative GalR-5-HT1A heteroreceptor complexes which may
contribute to depression (Figures 1–3). The Gal receptor subtype
was unknown. A role of raphe GalRs in depression and
the use of general GalR antagonists as novel antidepressant
drugs has been demonstrated (Bellido et al., 2002). An
increased density of GalRs was found in the dorsal raphe
of a genetic rat model of depression (Flinders sensitive line).
It may contribute to the development of the depressive
state though hyperpolarization of the 5-HT dorsal raphe
nerve cells leading to reduced firing in the ascending 5-HT
pathways to the forebrain. Again, the Gal receptor subtype is
unknown.
GalR1-5-HT1A Heteroreceptor Complexes
GalR1 homodimerization and internalization occurred in cellular
models (Wirz et al., 2005), while GalR1-5-HT1A heteroreceptor
complexes were found with FRET in HEK 293 cells (Borroto-
Escuela et al., 2010b). The observed FRET ratios were unaltered
by agonist treatments indicating that the heterocomplexes were
constitutive. The results obtained with CRE-luciferase and
SRE-luciferase reporter assays indicated possible antagonistic
allosteric receptor–receptor interactions in this heteroreceptor
complex. Thus, upon coactivation of the GalR1 and 5-HT1A
protomers, both coupled to Gi/o, no additional inhibition of AC
or stimulation of MAPK activity was observed in HEK293 cells.
It is possible that in depression this antagonistic allosteric
mechanism in the GalR1-5-HT1A heteroreceptor complexes is
dysfunctional which may lead to disturbances in their operation
in meso-limbic 5-HT neurotransmission.
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FIGURE 2 | The balance of the various serotonin 5-HT1A and galanin (GalR1 and GalR2) homo- and heteroreceptor complexes is indicated. Also the
5-HT1A-FGFR1 heteroreceptor complexes are presented, which have a role in depression. The allosteric receptor–receptor interactions induced constitutively or by
activation of one receptor protomer can influence the recognition, G protein coupling, signaling and trafficking of the other protomers in the homo and heteroreceptor
complex as indicated. The nature of the allosteric receptor–receptor interactions found in the individual heteromers is indicated in the top part of the receptor
complexes ([−] antagonistic allosteric modulation, [+] facilitatory allosteric modulation). The signaling of the receptor protomers reflects the signaling of the basal
states. For the abbreviations see Supplementary Material.
Dynamic GalR1-5-HT1A-GPR39
Complexes
GPR39 is a GPCR belonging to class A and represents a zinc
binding receptor (Holst et al., 2007). Recent results demonstrated
that zinc can disrupt the GalR1-5-HT1A heteroreceptor
complex which may contribute to its antidepressant actions
(Tena-Campos et al., 2015, 2016). In this process, GPR39 can
form a dynamic heterotrimeric receptor complex with
signaling diversity as demonstrated in cellular models
(Tena-Campos et al., 2015). It should also be noted that
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FIGURE 3 | The 5-HT1A hetero- and homoreceptor complexes shown as heterodimers are illustrated in the pre and postjunctional membranes of the
5-HT junctions. This represents a general hypothesis not specifically related to the raphe and/or hippocampus. In the right part the reorganization of the panorama
of the 5-HT1A heteroreceptor complexes in major depression are illustrated. Such reorganization can also take place in synapses and their peri and extrasynaptic
regions including inter alia glutamate synapses involving also changes in the balance of the 5-HT1A heteroreceptor complexes with their corresponding
homoreceptor complexes shown as hetero-and homodimers in the upper part. Also changes in 5-HT release may play a role in the 5-HT receptor reorganization.
This leads to changes in the integrative 5-HT receptor signaling including the multiple 5-HT receptor families and the various heteroreceptor complexes formed from
each of the 5-HT receptor subtypes. Thus, the barcodes of the 5-HT junctions and of inter alia glutamate and GABA synapses can be changed in depression. This
induces changes in the operation of the neuronal networks e.g., the raphe-hippocampal 5-HT system contributing to changes in cellular and behavioral responses
leading to major depression. For the abbreviations see Supplementary Material.
GPR39 knockout mice show indications of depression (Młyniec
et al., 2015) while zinc lowering produced a reduction of
GPR39 expression (Młyniec et al., 2013). It appears that
with high zinc levels, 5-HT1AR can no longer interact with
GalR1 and the 5-HT1A-GPR39 heteroreceptor complex
becomes the dominant form (Tena-Campos et al., 2015). The
heterotrimer complex may represent an intermediate form
dependent on zinc. This hypothesis offers one molecular
mechanism for the antidepressant actions of zinc based on
the ability of zinc binding receptor GPR39 to interact with
the 5-HT1A-GalR1 heteroreceptor complex and changing
the equilibrium towards GPR39-5-HT1A heteroreceptor
complexes.
GalR1-GalR2 Isoreceptor Complexes
Specific high affinity N-terminal Gal fragment (1–15) binding
sites in contrast to the Gal (1–29) high affinity binding
sites were early observed in the rat dorsal hippocampus,
neocortex and striatum (Hedlund et al., 1992, 1994). These
observations were made in spite of the fact that the three
cloned Gal receptors (GalR1, GalR2 and GalR3), show a
higher affinity for Gal than for Gal N-terminal fragments
(Branchek et al., 1998). It was therefore proposed that the high
affinity N-terminal Gal fragment binding sites developed in
GalR1–GalR2 heteroreceptor complexes due to conformational
changes in their GalR1 and/or GalR2 protomer recognition sites
(Fuxe et al., 2012c).
In line with this hypothesis, GalR1–GalR2 heteroreceptor
complexes were recently demonstrated in cellular models
using BRET and in the midbrain raphe-dorsal hippocampal
pathways of rodents using in situ PLA (Borroto-Escuela
et al., 2014b). Evidence was obtained that Gal (1–15) had
the ability to produce a disbalance of the signaling of
the GalR1–GalR2 heterodimer with enhanced activation of
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the Gi/o mediated signaling via the GalR1 protomer while
no significant effects were induced in the Gq/11 mediated
signaling of the GalR2 protomer. Such a disbalance in the
actions of Gal (1–15) on these isoreceptor complexes may
contribute to depression-like actions since such effects are
observed after treatment with GalR1 agonists (Fuxe et al.,
2012c).
It is of substantial interest that a relevant role for
the Gal N-terminal fragment (1–15) was found in anxiety-
and depression-related behaviors (Millón et al., 2014). The
strong depression-like and anxiogenic-like effects of the
Gal fragment disappeared in the siRNA GalR1 and siRNA
GalR2 receptor knockdown rats (Millón et al., 2014, 2016).
The behavioral actions of Gal (1–15) were markedly reduced
and related to the disappearance of the in situ PLA signals
and, thus, to the disappearance of the GalR1-GalR2 isoreceptor
complexes (Millón et al., 2014). Heterobivalent drugs with
GalR1 and GalR2 antagonist pharmacophors may specifically
target the GalR1 and GalR2 binding pockets of the GalR1-
GalR2 heteroreceptor complex, disrupt their function and
represent a new strategy for treatment of depression and
anxiety.
Putative GalR1-GalR2-5-HT1A
Heteroreceptor Complexes
Gal (1–15) in contrast to Gal (1–29) markedly enhanced the
antidepressant actions in the forced swimming test by the
5-HT1A receptor agonist 8-OH-DPAT (Millón et al., 2016)
probably through alterations in the allosteric receptor–receptor
interactions in the trimeric receptor complex. The effects
involved Gal (1–15) induced effects in 5-HT1A receptors
localized to the raphe-hippocampal 5-HT neuron system.
It was possible to demonstrate the existence of GalR1-
5-HT1A and GalR2-5-HT1A heteroreceptor complexes in
the dorsal hippocampus and in the dorsal raphe. These
results opened up the possibility that in fact the GalR1-
GalR2 heteroreceptor complex can form a dynamic trimeric
heterocomplex with the 5-HT1A receptor in these regions
involving both 5-HT1A postjunctional and autoreceptors. If so,
novel allosteric receptor–receptor interactions may be formed
in these trimeric complexes that has led to enhanced 5-HT1A
protomer signaling and enhanced anti-depressant effects in the
forced swimming test (Millón et al., 2016). Gal (1–15) was found
to increase the Kd and Bmax values and the mRNA levels of
the postjunctional 5-HT1A receptors in the dorsal hippocampus
but not of the 5-HT1A autoreceptors in the dorsal raphe.
The 5-HT1A autoreceptor complexes appear to be differentially
regulated with reduced mRNA levels in the dorsal raphe. Such
events can lead to enhancement of 5-HT1A receptor signaling
in the hippocampus and to enhanced firing of the ascending
5-HT neurons of the dorsal raphe. It is also possible that
the 5-HT1A receptor agonist 8-OH-DPAT, via an allosteric
receptor–receptor interactions, sets free Gq/11 signaling from
the GalR2 protomer, known to have antidepressant actions (Lu
et al., 2008), through allosteric inhibition of the GalR1 protomer
signaling.
Neuromodulation of Neuronal Networks in
Depression via 5-HT, Galanin Peptides and
Zinc Involving GPCR Heteroreceptor
Complexes
It appears clear that different types of 5-HT1A heteroreceptor
complexes containing also Gal R1, GalR2 protomers
and/or GalR1-GalR2 isoreceptor dimers with or without
GPR39 play a role in depression within the raphe-hippocampal
system including the ascending 5-HT neurons to the tel- and
diencephalon. The 5-HT1A receptor protomer remains a
receptor involved in modulating antidepressant activity
through its participation in the hetero and homoreceptor
complexes listed above. The heterocomplexes are in balance
with each other and exist especially in relation to the
raphe-hippocampal neuronal system (Figures 1–3). The
zinc binding receptor GPR39 may have an important
role in this context that needs to be defined and further
explored.
5-HT1A-FGFR1 Heteroreceptor Complexes
The demonstration of the FGFR1-5-HT1A heteroreceptor
complexes in the hippocampus increased our understanding
of how 5-HT1A receptors can enhance hippocampal plasticity
(Borroto-Escuela et al., 2012b). Marked increases in neurite
densities were inter alia found after agonist co-activation of
these heterocomplexes and antidepressant actions developed
upon combined icv treatment with FGF2 and a 5-HT1A
agonist. It was associated with increased phosphorylation of
FGFR1 and thus its activation, which can help counteract
depression induced atrophy of the hippocampus (Borroto-
Escuela et al., 2012b). A major neuromodulation appears to
develop since the coupling of the 5-HT1A receptors to the
GIRK channels appears to be reduced as well. This leads
not only to increases in trophism but also to increased
firing of hippocampal pyramidal nerve cells projecting directly
or indirectly into the prefrontal cortex and the reward
and anti-reward networks of the ventral striatum (Borroto-
Escuela et al., 2015a, 2016c). Similar events appear to take
place in the midbrain raphe with its rich presence of
FGFR1-5-HT1A autoreceptor complexes of high relevance for
neuroplasticity and depression (Borroto-Escuela et al., 2015c,d;
Figures 1–3).
Due to FGFR1 protomer activation, the 5-HT1A autoreceptor
function becomes diminished by its reduced coupling to GIRK
channels and the firing in the dorsal raphe 5-HT neurons
returns. Furthermore, the FGFR1 protomer activation can
increase trophism leading to the outgrowth of new 5-HT nerve
terminals including collaterals. Thus, the resulting enhancement
of 5-HT communication probably produces antidepressant
actions.
Similar events may also develop in the soma-dendritic
regions of the noradrenaline (NA) and DA neurons of the
locus coeruleus and ventral midbrain, respectively, in view
of the local existence of putative FGFR1-alpha2A-adrenergic
autoreceptor and FGFR1-D2 autoreceptor complexes. However,
this possibility remains to be explored. It should be noticed
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that deep brain stimulation results in plastic changes of the
central 5-HT neurons (Artigas, 2014; Veerakumar et al., 2014).
We should consider that such increases in plasticity can involve
activation of FGFR1-5-HT1A heteroreceptor complexes in the
dorsal raphe and in the hippocampus as well as FGFR1-5-
HT1B heteroreceptor complexes (Borroto-Escuela et al., 2012b,
2016c).
Neuromodulation of Neuronal Networks in
Depression via 5-HT and FGF2 Involving
FGFR1-5-HT1A Heteroreceptor Complexes
An exceptional degree of neuromodulation can develop in
ascending 5-HT pathways and in the hippocampus due to the
existence of allosteric receptor–receptor interactions of FGFR1-
5-HT1A heteroreceptor complexes in the midbrain raphe and
in the pyramidal cells of the hippocampus. This modulation
may correct both deficits in firing through antagonistic allosteric
interactions by reducing the coupling of the 5-HT1A receptor
to GIRK channels. With regard to trophism in the above
regions, agonist-induced 5-HT1A activation appears to increase
the trophic functions of the FGFR1 protomer (Borroto-Escuela
et al., 2012b) reinstating trophic activity in prefrontal and reward
networks of the forebrain. However, it is important to consider
that in depression the allosteric receptor–receptor interactions
in these heterocomplexes can be disturbed not only through
dysfunction of the allosteric receptor–receptor interactions but
also due to deficits in the formation of the FGFR1-5-HT1A
heterocomplexes.
5-HT1A Isoreceptor Complexes
The first discovered 5-HT1A isoreceptor complex in cellular
models was the 5-HT1A-5-HT7 complex in balance with 5-HT7-
5-HT7 and 5-HT1A-5-HT1A homoreceptor complexes (Renner
et al., 2012; Figures 2, 3) and the 5-HT1A-5-HT1B and 5-HT1A-
5-HT1D complexes (Salim et al., 2002). Heterodimerization
reduced the Gi/o mediated 5-HT1A signaling as well as the
ability of 5-HT1A to open the GIRK channels, also demonstrated
in the hippocampus. Furthermore, the heterodimerization was
critically participating in the 5-HT induced internalization
of the 5-HT1A protomer. It shows the impact of the
5-HT7 mediated allosteric receptor–receptor interactions on the
5-HT1A signaling and trafficking (Renner et al., 2012).
Very recently it was possible to demonstrate that the two
major 5-HT receptor subtypes 5-HT1A and 5-HT2A (Celada
et al., 2013) formed 5-HT1A-5-HT2A isoreceptor complexes in
the rat cortical regions including the hippocampus (Borroto-
Escuela et al., 2013c, 2016b). The 5-HT1A and 5-HT2A receptors
are previously known to be co-expressed in cortical regions
(Amargós-Bosch et al., 2004). The 5-HT isoreceptor complexes
were demonstrated with in situ PLA and in cellular models also
with BRET. The isoreceptor complexes were stress sensitive and
markedly reduced upon exposure to a forced swim session in
the hippocampus. An antagonistic allosteric receptor–receptor
interaction appeared to be in operation since a 5-HT2A agonist
upon activation of the 5-HT2A protomer markedly reduced the
affinity of the 5-HT1A protomer. These results indicate that the
5-HT2AR having prodepressive properties can do so in part by
directly inhibiting the recognition of the 5-HT1AR protomer,
known to possess antidepressant actions upon activation (Celada
et al., 2004). The early work in the 1970s showed that classical
antidepressant drugs can block one type of 5-HT receptor (Fuxe
et al., 1977; Ogren et al., 1979), likely the one identified as 5-HT2
(Peroutka and Snyder, 1979).
Neuromodulation of Neuronal Networks in
Depression via 5-HT Involving 5-HT
Isoreceptor Complexes
Antagonistic allosteric receptor–receptor interactions take place
in the 5-HT isoreceptor complexes discovered, at least with
regard to the 5-HT1A protomer of the 5-HT1A-5-HT7 (Renner
et al., 2012) and 5-HT1A-5-HT2A complexes (Borroto-Escuela
et al., 2016b). Thus, in the modulation process there appears to
exist a need in distinct states to produce an inhibition of certain
functions of the 5-HT1A protomer to optimize the modulation
of distinct networks.
The 5-HT1A receptor comes out as a hub receptor
participating in a large number of iso and heteroreceptor
complexes linked mainly to the raphe-hippocampal system of
the brain (Salim et al., 2002; Borroto-Escuela et al., 2010d,
2014a; Gorinski et al., 2012; Renner et al., 2012; Tena-Campos
et al., 2015). So far it is unknown which of the many 5-HT1A
iso-heteroreceptor complexes show the major disturbance in
major depression and should be the major target for novel
antidepressant drugs.
GPCR HETERORECEPTOR COMPLEXES
AND COCAINE USE DISORDER
It is true that small reductions of long duration exist in striatal
D2R availability and DA release of human cocaine addicts
(Volkow et al., 2011). However, the relevance of D2R for
cocaine use disorder was nevertheless shown in an article in
which chronic cocaine self-administration increases behavioral
responses mediated by D2Rs (Edwards et al., 2007). Furthermore,
chronic cocaine self-administration evoked persistent more than
100% elevations of D2R binding sites in the high affinity type
(Briand et al., 2008). Also D2R activation produced a strong
relapse of cocaine seeking in rats (Self, 2010; Wydra et al.,
2015b). The important role of D2R in cocaine use disorder was
also demonstrated by the findings that chronic escalating dose
‘‘binge’’ of cocaine administration was associated with a D2R-
stimulated G-protein activation and behavioral sensitization
(Bailey et al., 2008). This was observed in spite of a decreased
D2R density likely due to increased internalization (Bailey et al.,
2008). D2R forms a large number D2R heteroreceptor complexes
(Borroto-Escuela et al., 2014a; Fuxe et al., 2014e, 2015), some
of which are of high relevance for understanding cocaine use
disorder and its treatment (Figure 4).
A2A-D2 Heteroreceptor Complexes
It is of high interest that A2AR-D2R heteroreceptor complexes
with antagonistic allosteric receptor–receptor interactions
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FIGURE 4 | To the far left the ascending nigro-striatal and meso-limbic-cortical dopamine (DA) neurons are presented. The meso-limbic DA neurons play
a major role in cocaine addiction inter alia through their dense innervations of the nucleus accumbens shell with their D2R positive nerve cells regulating the brain
circuit from the nucleus accumbens shell to the prefrontal cortex. The first pathway is the ventral striato-pallidal GABA anti-reward system, rich inter alia in A2AR-D2R
heteroreceptor complexes. In the far right part the A2AR-D2R heteroreceptor complexes are visualized as red clusters in the nucleus accumbens shell using the
in situ proximity ligation assay (in situ PLA). To the left of this panel, sigma1R is seen as green immunofluorescence in nerve cell bodies in the nucleus accumbens
shell which likely mainly represent GABAergic projection neurons. In this region a large panorama of D2R heteroreceptor complexes exists in the accumbens
shell-ventral pallidal GABA anti-reward neurons modulating their activity (lower part). It represents previous work performed mainly in nuc accumbens (Fuxe et al.,
2014e,f). They play as major role in modulating these neurons and the panorama is reorganized in cocaine addiction and schizophrenia contributing to the
development of these diseases by increasing salience through inter alia removal of the brakes on the D2R protomer signaling found in distinct heterocomplexes. As
examples from the nucleus accumbens are shown: A2AR-D2R, 5-HT2AR-D2R, NTS1-D2R complexes given as heterodimers and A2AR-D2R-mGluR5 and
A2AR-D2R-sigma1R heterocomplexes given as heterotrimers (Cabello et al., 2009; Borroto-Escuela et al., 2010a,c,d, 2013b,c; Trifilieff et al., 2011). The A2A-D2
complexes are not located on the DA terminals and thus do not exist in a prejunctional position. Overall, the heteroreceptor complexes are mainly postjunctional on
dendrites-soma but some are located also on glutamate terminals like A2AR-D2R and NTS1-D2R heteroreceptor complexes (Tanganelli et al., 2004, 2012).The
scheme shown of heteroreceptor complexes in the figure does not itself give any indication of pre vs. post-junctional localization. For the abbreviations see
Supplementary Material.
were demonstrated in the ventral and dorsal striatum (Fuxe
et al., 1998; Trifilieff et al., 2011; Borroto-Escuela et al.,
2013c; Figures 4, 5). Such antagonistic allosteric A2AR-D2R
interactions have been demonstrated at the neurochemical
level (Frankowska et al., 2013; Wydra et al., 2015a) and in
behavioral models, including cocaine reward and cocaine
seeking in animals (Filip et al., 2006, 2012; Wydra et al., 2015b).
Our latter findings support a role of A2ARs in modulating
goal-maintained behaviors. They also indicate that increased
accumbal GABA release via an antagonistic A2AR-D2R
interaction can participate in mediating the inhibitory effects
of the A2AR agonist on cocaine reward (Wydra et al., 2015a).
Our results also indicate that A2AR activation and D2-like
receptor blockade counteract cocaine and food relapse. It is
proposed that A2AR- and D2R-mediated adenosine and DA
signaling antagonistically interact in the ventral striato-pallidal
GABA anti-reward neurons to regulate cocaine and food-seeking
behavior (Wydra et al., 2015b).
Such an increase in antagonistic allosteric plasticity in the
A2AR-D2R heteroreceptor complex can also help explain why
the A2AR agonist CGS 21680 produced a dose-dependent
blockade of the cocaine, quinpirole or cue induced reinstatement
of cocaine seeking (Wydra et al., 2015a,b). Our findings strongly
support the hypothesis that A2AR agonists targeting these
A2AR-D2R heteroreceptor complexes can represent a novel
treatment of cocaine use disorder.
Higher Order A2AR-D2R Heteroreceptor
Complexes: A2AR-D2R-sigma1R
Future work in the addiction research should inter alia focus
on multiple A2AR-D2R heteroreceptor complexes including
A2AR-D2R-sigma1R heterocomplexes (Navarro et al., 2010;
Pinton et al., 2015a,b) and their balance with each other and
the corresponding heterocomplexes. It is of high interest that
cocaine induces a selective increase of sigma1 receptors in the
ventral vs. the dorsal striatum (Romieu et al., 2002). Previous
work demonstrated that the sigma1Rs are involved in mediating
the pharmacological actions of cocaine and are potential targets
for the treatment of substance abuse (Maurice and Su, 2009). The
sigma1R is a chaperone protein located at the interface of the
endoplasmic reticulum and the mitochondrium (Hayashi and Su,
2007). It regulates several functional proteins including D1R and
D2R through oligomerization (Navarro et al., 2010, 2013) as well
as voltage gated Kv1.2 potassium channels (Kourrich et al., 2013).
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FIGURE 5 | The D2R heteroreceptor complexes illustrated in this figure are mainly found in the striatum. The balance of the various D2R homo and
heteroreceptor complexes are presented and their allosteric receptor–receptor interactions indicated. Also the NMDAR-D2R and OXTR-D2 heteroreceptor
complexes are presented, the latter having a role in social salience. The basal signaling of some of the D2R heteroreceptor complexes is indicated. The nature of the
allosteric receptor–receptor interactions found in the individual heteromers is indicated in the top part of the receptor complexes ([−] antagonistic allosteric
modulation, [+] facilitatory allosteric modulation). For the abbreviations see Supplementary Material.
It is of interest that sigma1R-D2R heteroreceptor complexes
can be formed while D3Rs and D4Rs cannot interact with
sigma1R (Navarro et al., 2010). Multiple interfaces appear
to exist between the sigma1R and D2R (Pinton et al.,
2015a,b). These heteroreceptor complexes were found with
in situ PLA in the ventral and dorsal striatum with highest
densities in the dorsal striatum (Pinton et al., 2015a,b). Romieu
et al. (2002) made the interesting observation that cocaine
selectively increased the sigma1R in the ventral striatum.
Instead Pinton et al. (2015b) and Borroto-Escuela et al. (2016d)
found the preferential development of antagonistic A2AR-D2R
interactions in the ventral striatum observed upon cocaine self-
stimulation. Supporting our latter finding, cocaine (100 nM)
enhances the D2R signaling in D2R-sigma1R heterocomplexes
but not in D2R mono-homomers, likely representing allosteric
modulations by cocaine induced by targeting the sigma1R
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protomer (Pinton et al., 2015a,b). Of particular relevance was
the demonstration that the A2AR agonist CGS 21680 markedly
reduced the ability of the D2R to inhibit the CREB signal
in the A2AR-D2R-sigma1R heteroreceptor complex of the
HEK293 cells in the presence of cocaine (100 nM; Pinton
et al., 2015a,b; Borroto-Escuela et al., 2016d). Such trimeric
heteroreceptor complexes may also exist in the nucleus
accumbens shell in view of a considerable co-distribution of
PLA positive A2AR-D2R and D2R-sigma1R heteroreceptor
complexes in this region.
The marked increase of sigma1R in the plasma membrane
induced by cocaine self-administration in the ventral striatum
likely participated in the local significant return of the
antagonistic allosteric A2AR-D2R interactions due to the
increased formation of A2AR-D2R-sigma1R heterocomplexes.
In this higher order receptor complex the A2AR-D2R interaction
appeared to become stronger probably via strong cocaine-
sigma1R interactions with restoration of significant and
enhanced antagonistic A2AR-D2R interactions. The A2AR-
D2R interactions were absent in the vehicle controls, since
under these conditions the sigma1R may have a higher
affinity for the D2R than for the A2AR-D2R heteroreceptor
complexes (Borroto-Escuela et al., 2016d; Pintsuk et al.,
2016b).
In contrast, in the dorsal striatum cocaine self-administration
does not produce sigma1R recruitment to the plasma
membrane (Romieu et al., 2002) and the antagonistic A2AR-
D2R interactions disappear. The major change produced
by cocaine may here be to elevate extracellular striatal
DA levels which is postulated to increase the affinity
for the formation of D2R homoreceptor complexes. As
a result there is a reduction in the number of A2AR-
D2R and A2AR-D2R-sigma1R heteroreceptor complexes
(Borroto-Escuela et al., 2016d).
Neuromodulation of Neuronal Networks in
Cocaine Use Disorder via DA and
Adenosine Signals Involving Multiple
A2AR-D2R Heteroreceptor Complexes
The modulation of the ventral striato-pallidal GABA anti-reward
neurons of the nucleus accumbens may have a critical
role in addiction development. It involves the DA and
adenosine volume transmission signals acting mainly on
extrasynaptic D2R and A2AR homo and heteroreceptor
complexes located on these anti-reward neurons. They are
hub receptors and form a large number of hetero and
isoreceptor complexes (Rocheville et al., 2000; Scarselli et al.,
2001; Dunham et al., 2009; So et al., 2009; Borroto-Escuela
et al., 2010e, 2014a; Przybyla and Watts, 2010; Verma et al.,
2010; Espinoza et al., 2011; Van Craenenbroeck et al., 2011;
Kern et al., 2012; Fuxe et al., 2014e, 2015; Figures 4, 5).
The balance between the various D2R and A2AR hetero
and homoreceptor complexes in the anti-reward system may
vary from one neuron to the other and each neuron may
have its own unique dynamic features in the panorama
of receptor complexes available which will determine its
neuromodulation. The ability of the individual neuron to
form sigma1R may have a crucial role in its ability to
mediate anti-cocaine action. The overall analysis so far strongly
indicates that the excitatory modulation of this anti-reward
system via targeting the A2AR-D2R and A2AR-D2R-sigma1R
heteroreceptor complex in which the sigma1R can act as an
adaptor protein holds high promise as a new way to treat
cocaine use disorder (Figure 4). Further studies are requested
to test how sigma1R agonists/antagonists may modulate the
anti-cocaine actions of A2AR agonists in the modulation of
the recognition and signaling of the A2AR-D2R heteroreceptor
complexes.
GPCR HETERORECEPTOR COMPLEXES
AND SCHIZOPHRENIA
Typical and atypical antipsychotics mainly act by targeting the
DA D2 receptors in the brain (Seeman et al., 2002; Kapur, 2003;
Ginovart and Kapur, 2010; Seeman, 2010). The critical D2Rs are
linked to the meso-limbic DA neurons in the ventral tegmental
area innervating densely, especially the nucleus accumbens core
and shell (Dahlstroem and Fuxe, 1964; Fuxe, 1965; Andén et al.,
1966). According to the DA hypothesis of schizophrenia, an
increased activity of meso-limbic DA neurons contributes to an
exaggerated release of DA from their nerve terminals mainly
operating via extrasynaptic volume transmission (Fuxe et al.,
2007, 2010a; Agnati et al., 2010). The resulting activation of the
extrasynaptic D2Rs may excessively inhibit the ventral striato-
pallidal GABA anti-reward neurons regulating a brain circuit
to the prefrontal cortex as described above under ‘‘cocaine
addiction’’ (Fuxe et al., 2008a,c, 2014e). Thus, it is important to
state that a similar dysregulation of the ventral striato-pallidal
GABA anti-reward neurons takes place in schizophrenia and in
cocaine addiction.
Therefore, in schizophrenia with a silenced anti-reward
system most stimuli obtain salience which may lead to symptoms
like delusions in order to make sense out of the pathological
interpretation of sensory inputs. The patients live in a world
where all stimuli are of relevance (Kapur, 2003). A major action
of the D2R antagonists should be to bring down salience without
fully blocking it.
A breakthrough developed in the DA D2R field and its link
to schizophrenia when different types of D2R heteroreceptor
complexes were discovered in the forebrain (Fuxe et al., 1998;
Hillion et al., 2002; Liu et al., 2006; Borroto-Escuela et al.,
2013c, 2014c, 2016a; Figure 5). It opened up the possibility to
pharmacologically reduce D2R function only in certain D2R
heteroreceptor complexes that were disturbed in schizophrenia
while others were not targeted by the novel antipsychotics to
avoid side effects.
The D2R is a hub receptor which can interact with
isoreceptors and other GPCRs (Borroto-Escuela et al., 2014a)
but also with NMDAR (Liu et al., 2006), DA transporters
and Disc1 (Su et al., 2014) which leads to diversity and bias
(Fuxe et al., 2014f). Also receptor-protein interactions in higher
order heteroreceptor complexes have become of importance
in schizophrenia involving neuronal adhesion and scaffolding
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proteins formed from susceptibility genes (de Bartolomeis
et al., 2013). The integrative process in higher order D2R
heteroreceptor complexes have become increasingly complex
and represent an important area for future research in
schizophrenia.
Mainly the D2R-GPCR heteroreceptor complexes in the
ventral and dorsal striatum will be discussed in relation to the
ventral striato-pallidal GABA anti-reward neurons and their
modulation of the brain circuit to the prefrontal cortex with
impact on schizophrenia.
Multiple A2AR-D2R Heteroreceptor
Complexes
These heterocomplexes were already discussed in relation to
cocaine addiction. In animal models of schizophrenia the
A2AR agonist CGS 21680 behaves as an atypical antipsychotic
(Rimondini et al., 1997). It can act as a negative allosteric
modulator over the A2AR-D2R interface to reduce D2R
protomer affinity in the high affinity state and Gi/o mediated
D2R signaling in this heteroreceptor complex (Fuxe et al., 1998).
A modest blockade of this D2R protomer will therefore more
easily be obtained with reduced signs of depressive actions
compared with D2R antagonists. The contribution of A2A
agonist actions at the A2A monomer-homoreceptor complexes
should also be considered in increasing activity in the striato-
pallidal GABA anti-reward pathway (Fuxe et al., 2014c,d;
Borroto-Escuela et al., 2015b,e, 2016d).
The amphetamine-induced sensitized state is a rat
model of schizophrenia (Seeman et al., 2002). It therefore
became of interest to study changes in the ventral and
dorsal striatal allosteric A2AR-D2R receptor–receptor
interactions in this model after an acute amphetamine
challenge (Pintsuk et al., 2016a). As tested ex vivo with the
A2AR agonist CGS 21680, there was a reinstatement of the
antagonistic A2AR-D2R interaction in the ventral but not
in the dorsal striatum after acute amphetamine treatment
in the amphetamine sensitized state compared with the
saline sensitized state. These actions of the A2AR agonist
obtained in a rat model of schizophrenia can help explain its
atypical antipsychotic profile (Pintsuk et al., 2016a). Instead
the failure to produce antagonistic A2AR-D2R interactions
in the dorsal striatum can assist to the development of the
amphetamine-induced sensitized state shown as increases
in locomotion.
It is of high interest that in this rat model of schizophrenia
an increase in the D2R homodimerization was found in the
dorsal striatum (Wang et al., 2010). Such an increase was also
found in postmortem striatum from patients with schizophrenia.
The absence of the antagonistic A2AR-D2R interactions in
the dorsal striatum from rats in the amphetamine-induced
sensitized state may therefore be due to the dominance of D2R
homodimers over A2AR-D2R heteroreceptor complexes. It is
suggested that the amphetamine-induced DA release in the
dorsal striatum through the activation of the D2R orthosteric
sites can enhance the affinity of the D2R protomers for each
other leading to increased D2R homodimerization (Borroto-
Escuela et al., 2015e, 2016d). A differential modulation of the
A2AR-D2R heteroreceptor complexes and their balance with
D2R and A2AR homoreceptor complexes likely develops in the
ventral striatum of the amphetamine-induced sensitized state.
It may be as seen after cocaine self-administration (Pintsuk
et al., 2016b) that increases in sigma1R levels develop which can
increase the formation A2AR-D2R-sigma1R with strong A2AR-
D2R interactions.
The salience dysregulation in schizophrenia (Winton-Brown
et al., 2014) appears linked to hyperactivity in the meso-limbic
DA neurons (Grace, 2017) and to deficient brakes on D2R
protomer signaling in its inhibition of the ventral-striato-pallidal
anti-reward system involving inter alia multiple A2AR-D2R
heteroreceptor complexes.
Also A2AR-D2R-mGluR5 heterocomplexes appear to exist
in the ventral striato-pallidal GABA anti-reward pathway
(Figure 5). In line with this view, it was indicated based
on the codistribution of high densities of A2AR-D2R and
A2AR-mGluR5 in situ PLA positive complexes in nucleus
accumbens that A2AR-D2R-mGluR5 heterotrimeric complexes
may exist in these anti-reward neurons (Borroto-Escuela et al.,
2015b, 2016a). It was previously demonstrated in cellular
models that A2AR-D2R-mGluR5 form trimeric heteroreceptor
complexes using bimolecular fluorescence complementation
and bioluminescence resonance energy transfer techniques
(Cabello et al., 2009). They exist perisynaptically to glutamate
synapses located on the striato-pallidal GABA neurons. The
A2AR and mGluR5 protomers synergistically counteract the
D2R recognition and signaling in these complexes (Ferré
et al., 2002; Fuxe et al., 2003) and combined treatment with
A2AR agonists and mGluR5 agonists/positive allosteric
mGlu5 modulators should be a novel promising strategy
for treatment of schizophrenia (Wieronska et al., 2016) with
or without the use of D2R antagonists. Heterobivalent drugs
built up of A2AR agonist and mGluR5 agonist/mGlu5 positive
modulator pharmacophors should be interesting new drugs
specifically targeting the A2AR-mGluR5 heteroreceptor
complexes. Such compounds will also be of high interest for
treatment of cocaine use disorder, since these heterocomplexes
exist in the striato-pallidal GABA anti-reward system, highly
relevant also for the treatment of cocaine use disorder (see
above).
Neuromodulation of Neuronal Networks in
Schizophrenia via DA, Adenosine and
Glutamate Signals Involving Multiple
A2AR-D2R Heteroreceptor Complexes
As in cocaine use disorder, the ventral striato-pallidal GABA
anti-reward system is of major importance also in schizophrenia.
Major modulators of this anti-reward system are again DA
and adenosine mainly operating via volume transmission
and also glutamate operating mainly via synaptic but also
via volume transmission. The balance of these signals and
in the panorama of especially A2AR-D2R, A2AR-mGluR5,
A2AR-D2R-mGluR5 and A2AR-D2R-sigma1R heteroreceptor
complexes and their homoreceptor correlates will have a relevant
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impact on the activity of this anti-reward system and thus
on the salience of the incoming sensory stimuli (Figure 4). It
remains to be demonstrated which of these D2R heteroreceptor
complexes are mainly disturbed in schizophrenia with a reduced
brake on D2R protomer signaling leading to increases in
schizophrenic symptoms. It should be considered that like
in cocaine use disorder the synthesis and transport of the
chaperone protein sigma1R to the plasma membrane can also
play a relevant role in schizophrenia through its participation
in a number D2R heteroreceptor complexes including A2AR-
D2R-sigma1R. As discussed, there are indications that the
sigma1R brings about an increase in the antagonistic A2AR-
D2R interaction (Pinton et al., 2015a,b; Borroto-Escuela et al.,
2016d).
Multiple NMDA Heteroreceptor Complexes
There is an agreement that hypofunction of NMDA
receptors play a significant role in the pathophysiology
of schizophrenia contributing especially to the cognitive
and negative symptoms of this disease (Balu, 2016). The
anti-psychotic actions of mGluR5 activation discussed
above also appear to involve facilitatory allosteric
receptor–receptor interactions at mGluR5-NMDA
heteroreceptor complexes within glutamate synapses
(Wieronska et al., 2016).
Of high interest are also the findings of D2R-NMDA
heteroreceptor complexes with the D2R protomer linked to the
NR2B subunit (Liu et al., 2006). This group demonstrated that
the allosteric receptor–receptor interaction produced a reduced
ability of Ca2+/calmodulin dependent protein kinase II to bind
to NR2B. As a consequence, a reduced phosphorylation of the
NR2B subunit takes place followed by a decrease of NMDA
receptor signaling. Of particular relevance for schizophrenia may
be the existence of this complex in the glutamate synapses of the
ventral striato-pallidal GABA anti-reward neurons.
Neuromodulation of Neuronal Networks in
Schizophrenia via DA and Glutamate
Signals Involving Multiple NMDA
Heteroreceptor Complexes
The neuromodulation of the ventral striatal-ventral pallidal-
mediodorsal thalamic-prefrontal cortical circuit is again of
special interest (Fuxe et al., 2008a,b,c) in view of its role in
salience. Salience in schizophrenia becomes exaggerated due
inter alia to the dysregulation of D2Rs in certain types of
D2R heteroreceptor complexes. Also as a reduced function
in certain types of NMDA heteroreceptor complexes located
inter alia on the striato-pallidal anti-reward neurons. It is of
substantial interest that overactivity of DA nerve terminals
may release increased amounts of DA to diffuse into the
glutamate synapses and its perisynaptic regions on the GABA
anti-reward neurons to bring down NMDA receptor signaling
and thus the glutamate drive on the anti-reward neurons.
The D2R-NMDA heteroreceptor complexes may therefore be
at the heart of the dysregulation of the anti-reward neurons
in schizophrenia together with the perisynaptic A2AR-D2R-
mGluR5 heteroreceptor complexes where inhibitory D2R
signaling becomes preferred by the allosteric receptor–receptor
interactions. In the glutamate synapse the D2R-NMDA
heteroreceptor complex is proposed to be in dominance
in the balance with the mGluR5-NMDA complex where
the trimer mGluR5-NMDA-D2R can be an intermediate
form.
It seems possible that certain anti-reward neurons
may possess both D2R-NMDA and A2AR-D2R-
mGluR5 heteroreceptor complexes in glutamate synapses and
perisynaptic regions, respectively (Figure 5). They may be more
efficiently silenced by over activated D2Rs in schizophrenia than
many other anti-reward neurons and more strongly contribute
to the schizophrenic symptoms.
5-HT2AR-D2R Heteroreceptor Complexes
These heteroreceptor complexes were demonstrated with
the BRET technique in cellular models and then with in situ
PLA in the dorsal and ventral striatum including nucleus
accumbens core and shell (Borroto-Escuela et al., 2010d,
2013c, 2014c; Albizu et al., 2011). It is of high interest
that the hallucinogenic but not standard 5-HT2A agonists
produced an enhancement of D2R protomer signaling via
the 5-HT2AR protomer in the 5-HT2AR-D2R heteroreceptor
complex. It therefore seems possible that in schizophrenia
a pathological allosteric enhancement of the D2R signaling
takes place after 5-HT activation of the 5-HT2AR protomer,
without use of hallucinogenic 5-HT2A agonists. Such a
mechanism can be one factor that explains why the high
potency of many atypical anti-psychotics like risperidone
and clozapine to block 5-HT2ARs can be a valuable action
(Meltzer et al., 1989, 2010). An inverse 5-HT2AR agonist
pimavanserin exerts antipsychotic actions especially in
Parkinson’s disease (Meltzer et al., 2010; McFarland et al.,
2011). It may be that L-DOPA and D2R agonist treatments
have produced alterations inter alia in the stoichiometry and
in the allosteric receptor–receptor interactions of the D2R-5-
HT2AR heteroreceptor complexes, which makes them more
vulnerable to the blocking effects of this inverse 5-HT2AR
agonist.
Neuromodulation of Neuronal Networks in
Schizophrenia via DA and 5-HT Signals
Involving 5-HT2AR-D2R Heteroreceptor
Complexes
Through extrasynaptic volume transmission, 5-HT may activate
the 5-HT2AR protomer of the 5-HT2AR-D2R heteroreceptor
complexes which in the nucleus accumbens core and shell
may mainly be located on the ventral striato-pallidal GABA
anti-reward neurons. It is unknown if these neurons are
different from the anti-reward neurons containing the multiple
A2AR-D2R heteroreceptor complexes or if these types of
complexes overlap with each other as studied with the
in situ PLA. It will be important to establish if each striato-
pallidal GABA neuron has its own unique panorama of D2R
heteroreceptor complexes located in distinct positions along
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the dentrites, soma and terminals. The question is which D2R
heteroreceptor complexes show the highest vulnerability in
schizophrenia.
NTS1-D2 Heteroreceptor Complexes
Antagonistic NTS1-D2R interactions were early on discovered
in the dorsal and ventral striatum (Agnati et al., 1983b; Von
Euler and Fuxe, 1987) and later on shown to take place in
NTS1-D2R heteroreceptor complexes in cellular models using
BRET (Koschatzky et al., 2011; Borroto-Escuela et al., 2013b)
and in the ventral and dorsal striatum using in situ PLA
(Figure 4). Using CRE luciferase gene assay it was found
that NTS1 activation produced a strong blockade of the D2R
induced inhibition of the AC-PKA-CREB pathway (Borroto-
Escuela et al., 2013b). The inhibitory modulation by NTS1 of
D2R recognition and signaling appeared to have a major
location in the cortico-accumbens glutamate terminals on the
ventral striato-pallidal GABA anti-reward neurons leading to
increased glutamate release and activation of the anti-reward
neurons (Ferraro et al., 2008, 2012, 2014). Such antagonistic
NTS1-D2R interactions at the soma-dendritic level of these
neurons can also contribute to this activation of the anti-reward
neurons and thus to the anti-psychotic like actions of NT
peptides (Ferraro et al., 2014). Also facilitatory NTS1-NMDAR
receptor–receptor interactions were observed in the nucleus
accumbens that can contribute to the anti-psychotic actions
based on the hypofunction of NMDAR in schizophrenia (Ferraro
et al., 2012, 2014). In the ventral midbrain, however, they can
contribute to propsychotic actions due to their activation of the
meso-limbic DA neurons.
Neuromodulation of Neuronal Networks in
Schizophrenia via DA, NT Peptides, and
Glutamate Signals Involving NTS1-D2R
and Putative NMDA-NTS1 Heteroreceptor
Complexes
Neurotensin peptides are formed inter alia in neurons of the
striatum and communicate via volume transmission to activate
especially NTS1 receptors to inhibit D2R signaling and enhance
NMDA signaling in NTS1-D2R and putative NTS1-NMDA
heteroreceptor complexes, respectively linked to the anti-reward
neurons. Thus, this modulation by the NT peptides increases
glutamate release and activity in the anti-reward neurons. In
this way reduced salience develops and schizophrenic symptoms
are diminished. It has not been determined how the NTS1-D2R
in situ PLA positive clusters overlap with the A2AR-D2R and
5-HT2AR-D2R positive PLA clusters in the GABA anti-reward
neurons enriched in the D2Rs. Nevertheless, the NTS1-D2R and
NTS1-NMDAR complexes have a substantial location in the
accumbens glutamate nerve terminals.
D2-oxytocinR Heteroreceptor Complexes
In classical studies it was shown by Insel and Young (2001)
and his group that striatal oxytocin receptors play a key
role in inducing the pair bonding found in the monogamous
prairie vole female and that the D2Rs play an important role
in the social attachment process (Gingrich et al., 2000; Insel
and Young, 2001; Young and Wang, 2004). Coactivation of
D2R and oxytocin receptors appears essential for the social
attachment (Fuxe et al., 2012b). Evidence was obtained that
the molecular mechanism mediating the social salience was
the formation of D2R-oxytocinR heteroreceptor complexes in
the dorsal striatum and especially in the nucleus accumbens
core as shown with in situ PLA (Romero-Fernandez et al.,
2013; Figure 5). In these heterocomplexes oxytocin via
allosteric receptor–receptor interactions markedly increased
D2R recognition (increased affinity of the high affinity state
and increased density of D2Rs) and increased D2R Gi/o
coupling. These effects of oxytocin were all blocked by an
oxytocin receptor antagonist L368,899 (Romero-Fernandez et al.,
2013). Signaling in DA D2R-oxytocin receptor heterocomplexes
were also studied (de la Mora et al., 2016). Oxytocin was
found to enhance the D2R-like agonist quinpirole induced
inhibition of the AC-PKA-pCREB signaling cascade and
quinpirole enhanced the oxytocin induced increases in the
activity of the PLCbeta-IP3-calcineurin pathway in cellular
models. These results are highly relevant for the role of the
oxytocin and DA interactions in social attachment and their
anxiolytic effects in the amygdala of the rat (de la Mora et al.,
2016).
Neuromodulation of Neuronal Networks in
Schizophrenia via DA and Oxytocin,
Involving D2R-oxytocinR Heteroreceptor
Complexes
The oxytocin pathways from the paraventricular nucleus
and the DA pathways from the ventral midbrain project
into the nucleus accumbens and the dorsal striatum where
the oxytocin and DA nerve terminal networks co-distribute
(Fuxe et al., 2010a, 2012b). They communicate mainly via
volume transmission to act inter alia on the D2R-oxytocinR
heteroreceptor complexes where they enhance the signaling
of each other via allosteric receptor–receptor interactions. We
postulate that the role of these integrative D2R-oxytocinR
heterocomplexes is to markedly increase social salience by
being located to a special component of the ventral striato-
pallidal GABA neurons involved in regulating a brain circuit
reaching into the prefrontal cortex. As a result of the
activation of the D2R-oxytocinR heteroreceptor complex the
information passing into the prefrontal cortex will produce
social attachment and trust and the negative symptoms of
schizophrenia may become markedly reduced. It was also
proposed that oxytocin can induce antipsychotic actions
(Caldwell et al., 2009) which appears to be true after being
given to schizophrenic patients intranasally (Feifel et al., 2010;
Feifel, 2012). Based on our hypothesis, the failure of D2R
antagonists to reduce negative symptoms of schizophrenia is
due to the blockade of D2R protomers in the D2R-oxytocinR
heterocomplexes. For treatment of deficits in social interactions
in schizophrenia, we propose as treatment strategy the use
of heterobivalent drugs with oxytocin and D2R agonist
Frontiers in Cellular Neuroscience | www.frontiersin.org 14 February 2017 | Volume 11 | Article 37
Borroto-Escuela et al. Understanding GPCR Heteroreceptor Complexes
pharmacophors that can specifically target these heteroreceptor
complexes. It may also be possible to find D2R antagonists
with low potency to block the D2R protomers of these
heteroreceptor complexes. Another alternative is also the use of
combined treatment with oxytocin and a D2R agonist which
preferentially target the D2R protomer in the D2R-oxytocinR
heterocomplex.
CONCLUDING REMARKS
The neuromodulation is induced via the allosteric
receptor–receptor interactions in isoreceptor and heteroreceptor
complexes and changes in their balance with each other
and homoreceptor complexes. Such a neuromodulation
may play a major role in the regulation of brain circuits.
This is true especially for neuronal networks of depression,
addiction and schizophrenia. The most exciting development
in this field is the plasticity of the synaptic and extrasynaptic
heteroreceptor complexes at pre and postjunctional level (Fuxe
and Borroto-Escuela, 2016) and of their balance as found
e.g., after cocaine self-administration (Borroto-Escuela et al.,
2016d). The transmitters working via synaptic and/or volume
transmission (Fuxe et al., 2010a; Borroto-Escuela et al., 2015a)
may have a significant role in determining this plasticity through
changes in the formation and stability of the panorama of
hetero and homoreceptor complexes in balance with each other.
This plasticity may in fact be altered in CNS disease leading to
altered neuromodulation and dysfunction of the brain circuits
with deficits in learning and memory (Fuxe et al., 2014a,b;
Borroto-Escuela et al., 2015a) and in emotions and motivation.
As new drugs for specifically targeting the heteroreceptor
complexes heterobivalent compounds are being developed since
several years with agonist and/or antagonist pharmacophors
(Daniels et al., 2005; Waldhoer et al., 2005; Soriano et al.,
2009; Huber et al., 2012; Hübner et al., 2016). Structure-guided
development of heterodimer selective GPCR ligands is currently
being performed targeting the NTS1-D2R heteromers (Hübner
et al., 2016). The hope is that such types of drugs including also
heterobivalent drugs that can target allosteric binding sites can
become drugs for the future in the treatment of neurological and
mental disorders.
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